Latest From NxThera Inc.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
With $1 billion under management, Hong Kong-based private equity firm Ally Bridge Group bagged multiple deals in 2015 including WuXi's $3.3 billion privatization. ABG's CEO Frank Yu talks about pursuing a holistic approach that goes beyond ABG's China roots.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced November-December 2015.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Gynecological, Urological
- Renal System
- North America
- Parent & Subsidiaries
- NxThera Inc.
- Senior Management
J. Robert Paulson, Pres. & CEO
Carmen Bringgold, CFO & Chief Compliance Officer
Mona Dahdah, VP, R&D & Operations
Michael Hoey, CTO
Michael Kujak, Chief Mktg. Officer & VP, International Sales
Kathy Simpson, VP, Quality & Reg. Affairs
Cindy Ogden, VP, Clinical Affairs
- Contact Info
Phone: (763) 515-0404
7351 Kirkwood Lane North
Maple Grove, MN 55369
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.